Department of Pediatrics, Divisions of Pediatric Critical Care, Emory University, Atlanta, GA, USA.
Pediatr Crit Care Med. 2011 Mar;12(2):153-8. doi: 10.1097/PCC.0b013e3181e2a596.
To assess the outcome of pediatric patients supported by concomitant extracorporeal membrane oxygenation (ECMO) and continuous renal replacement therapy (CRRT).
DESIGN, SETTING, AND PATIENTS: Acute kidney injury is associated with mortality in ECMO patients. CRRT in patients on ECMO provides an efficient and potentially beneficial method of acute kidney injury management. Concern that concomitant CRRT use increases the risk of developing anuria and chronic renal failure limits its use in some centers. We hypothesized that development of chronic renal failure is rare with concurrent ECMO and CRRT. We evaluated the outcomes of 154 ECMO/CRRT patients cared for over 10 yrs at a referral pediatric medical center.
None.
Among 68 (44%) ECMO/CRRT survivors, 45 were assigned a pediatric risk, injury, failure, loss and end-stage (referred to as "pRIFLE") score at CRRT initiation. Seventeen (38%) patients met the criteria for Risk, 15 (33%) for Injury, and 10 (22%) for Failure. Two Failure patients later met End stage criteria. Of all survivors, 18 (26%) required ongoing renal replacement therapy (15 required continuous veno-venous hemofiltration, two required peritoneal dialysis, and one patient required intermittent hemodialysis) post ECMO discontinuation. Renal recovery occurred in 65 (96%) of 68 patients before discharge. One neonatal patient had sepsis-induced renal injury on transfer, but had normal creatinine 1 month later. Two pediatric patients with vasculitis and primary renal disease at presentation (both meeting Failure criteria) developed end-stage renal disease. One received peritoneal dialysis and subsequent renal transplant. The other has diminished function without need for renal replacement therapy.
In the absence of primary renal disease, chronic renal failure did not occur after concurrent use of CRRT with ECMO. Concern for precipitating chronic renal failure by using CRRT during ECMO is not substantiated by this large single-center experience. Consistent with previous reports, mortality is higher in patients receiving concomitant CRRT and ECMO compared with those receiving ECMO alone. Mortality is similar to patients requiring CRRT who are not on ECMO. Additional studies are warranted to determine the optimal role of CRRT use in ECMO patients.
评估同时接受体外膜肺氧合(ECMO)和持续肾脏替代治疗(CRRT)支持的儿科患者的结局。
设计、设置和患者:急性肾损伤与 ECMO 患者的死亡率相关。ECMO 患者的 CRRT 提供了一种有效且可能有益的急性肾损伤管理方法。一些中心担心同时使用 CRRT 会增加发生无尿和慢性肾衰竭的风险,因此限制了其使用。我们假设同时使用 ECMO 和 CRRT 很少会导致慢性肾衰竭。我们评估了在一家转诊儿科医疗中心接受超过 10 年治疗的 154 例 ECMO/CRRT 患者的结局。
无。
在 68 例(44%)ECMO/CRRT 存活者中,45 例在开始 CRRT 时被分配了儿科风险、损伤、衰竭、损失和终末期(简称“pRIFLE”)评分。17 例(38%)患者符合风险标准,15 例(33%)符合损伤标准,10 例(22%)符合衰竭标准。2 例衰竭患者后来符合终末期标准。所有存活者中,18 例(26%)在 ECMO 停止后需要持续肾脏替代治疗(15 例需要连续静脉-静脉血液滤过,2 例需要腹膜透析,1 例需要间歇性血液透析)。68 例患者中,65 例(96%)在出院前恢复了肾功能。1 例新生儿在转院时因感染性休克导致肾损伤,但 1 个月后肌酐正常。2 例有血管炎和原发性肾病的儿科患者在发病时(均符合衰竭标准)发展为终末期肾病。1 例患者接受了腹膜透析和随后的肾移植。另 1 例患者肾功能减退,无需肾脏替代治疗。
在没有原发性肾脏疾病的情况下,同时使用 ECMO 和 CRRT 后不会发生慢性肾衰竭。本研究为单中心大样本研究,并未证实在 ECMO 期间使用 CRRT 会引发慢性肾衰竭的担忧。与之前的报告一致,同时接受 CRRT 和 ECMO 治疗的患者死亡率高于仅接受 ECMO 治疗的患者。死亡率与未接受 ECMO 但需要接受 CRRT 治疗的患者相似。需要进一步的研究来确定 CRRT 在 ECMO 患者中的最佳应用。